Tissue Regenix (LON:TRX) cover image
132 Reads (2 mins read)

Three threats to the Tissue Regenix share price

17th May by Jack Brumby

As an investor, I want to know that I can rely on the accounts of the companies I buy shares in - and I bet you do too.

What most investors don’t realise is that there are algorithmic ways to check the credibility of company earnings - and one of them is called the Beneish M-Score. In this article I’m going to explain how it works by looking at Tissue Regenix (LON:TRX) as an example.

GET MORE DATA-DRIVEN INSIGHTS INTO LON:TRX »

About Tissue Regenix (LON:TRX)

Tissue Regenix is a speculative, small cap in the Biotechnology & Medical Research industry. The medical technology company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues

In terms of price performance, the Tissue Regenix share price has seen 1-year relative strength against the FTSE All-Share index of -43.5%.

While those figures sound promising, the Beneish M-Score - which I’ll explain shortly - shows that there are areas in Tissue Regenix's accounts that might be worth closer investigation.

It's important to note that this doesn’t mean that Tissue Regenix is doing anything wrong. But it does mean that the risks could be higher than for other shares. As an investor, you should know what these red flags mean - both in Tissue Regenix and any other stock you might be thinking of buying.

How the Beneish M-Score works

In 1999, a finance professor called Messod Daniel Beneish published a landmark research paper entitled The Detection of Earnings Manipulation. It showed how you can use accounting data to spot problems early.

Since then it’s become an indispensable checklist for professional money managers and investment banks - and you can use it too.

Professor Beneish’s M-Score looks at the year-on-year change in eight different ratios that can be worked out from a company’s financial statements. It looks for these red flags:

  • Inflated revenues
  • Declining gross margins
  • Capitalised and deferred costs
  • Excessive sales growth
  • Lengthening depreciation periods
  • Rising sales expenses
  • Increasing leverage
  • Higher accruals

Ideally, you and I would want our stocks to be passing these checks with ease. But when a company fails one or more of them, it’s time to dig deeper into the accounts to find out why.

Are there accounting risks at Tissue Regenix?

Here is a graphic that shows how Tissue Regenix stacks up against the M-Score checklist.

5cde82420be3dimage.png

Next steps

Armed with this information, you might want to explore the accounts on Tissue Regenix's StockReport to understand what the red flags mean and whether they point to possible risks.

In addition, you can use this Beneish M-Score Cheat Sheet to check for earnings manipulation risks in any stock in the market. You can also check to see which other stocks fail the Beneish M-Score test with this constantly updated screen.

Share this article
As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.
Share Price
3.9p
Change Today
0%
Tissue Regenix ( )

Stockopedia is here to help individual investors beat the markets by being the very best in stock analysis, research & community. Take a 30 day free trial of our extensive multi-award winning service and find out why more than ten thousand global investors can't live without it.

© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.